Biocon Tech Stack

Biocon uses 8 technology products and services including Lightbox, RSS, Bootstrap, and more. Explore Biocon's tech stack below.

  • Lightbox
    Javascript Libraries
  • RSS
    Miscellaneous
  • Bootstrap
    UI Frameworks
  • Breadcrumb NavXT
    Web Platform Extensions
  • Apache HTTP Server
    Web Servers
  • Apache
    Web Servers
  • Pinterest
    Widgets
  • AddToAny
    Widgets

Media & News

Biocon's Email Address Formats

Biocon uses at least 4 format(s):
Biocon Email FormatsExamplePercentage
first.middle@biocon.comJohn.Michael@biocon.com
50%
firstmiddle.last@biocon.comJohnMichael.Doe@biocon.com
32%
last.first@biocon.comDoe.John@biocon.com
11%
firstlast@biocon.comJohnDoe@biocon.com
7%

Frequently Asked Questions

Where is Biocon's headquarters located?

Minus sign iconPlus sign icon
Biocon's main headquarters is located at Hosur Road, Electronics City Bangalore, Karnataka 560100 IN. The company has employees across 6 continents, including AsiaNorth AmericaEurope.

What is Biocon's phone number?

Minus sign iconPlus sign icon
You can contact Biocon's main corporate office by phone at +1-732-636-2950. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Biocon's stock symbol?

Minus sign iconPlus sign icon
Biocon is a publicly traded company; the company's stock symbol is BICO1.

What is Biocon's official website and social media links?

Minus sign iconPlus sign icon
Biocon's official website is biocon.com and has social profiles on LinkedIn.

How much revenue does Biocon generate?

Minus sign iconPlus sign icon
As of April 2024, Biocon's annual revenue reached $501B.

What is Biocon's SIC code NAICS code?

Minus sign iconPlus sign icon
Biocon's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Biocon have currently?

Minus sign iconPlus sign icon
As of April 2024, Biocon has approximately 11K employees across 6 continents, including AsiaNorth AmericaEurope. Key team members include Chief Executive Officer: L. R.Chief Executive Officer: D. D.Chief Financial Officer: I. S.. Explore Biocon's employee directory with LeadIQ.

What industry does Biocon belong to?

Minus sign iconPlus sign icon
Biocon operates in the Biotechnology Research industry.

What technology does Biocon use?

Minus sign iconPlus sign icon
Biocon's tech stack includes LightboxRSSBootstrapBreadcrumb NavXTApache HTTP ServerApachePinterestAddToAny.

What is Biocon's email format?

Minus sign iconPlus sign icon
Biocon's email format typically follows the pattern of first.middle@biocon.com. Find more Biocon email formats with LeadIQ.

How much funding has Biocon raised to date?

Minus sign iconPlus sign icon
As of April 2024, Biocon has raised $129M in funding. The last funding round occurred on Feb 22, 2023.

When was Biocon founded?

Minus sign iconPlus sign icon
Biocon was founded in 1978.
Biocon

Biocon

Biotechnology ResearchKarnataka, India5001-10000 Employees

 

Biocon: Enhancing Global Healthcare

Biocon Limited, publicly listed in 2004, is India's largest and fully-integrated, innovation-led biopharmaceutical company. It is an emerging global biopharmaceutical enterprise serving customers in over 120 countries. Driven by a vision to enhance global healthcare through innovative and affordable biopharmaceuticals, we have enabled access to advanced therapies for diseases that are chronic, where medical needs are largely unmet and treatment costs are high. 

The early anticipation of the increasing dominance of biologics in global development pipelines helped us to be ahead of the curve in crafting a differentiated product portfolio based on fermentation and recombinant technologies, which straddles fermentation-derived small molecules and biologics, both novel as well as biosimilars.

The significant brand equity that we have built worldwide for our small molecule APIs across statins, immunosuppresants and other specialty products has made us a leading global supplier of these products.

We have also built one of the largest and most diverse biosimilar pipelines, spanning insulins, monoclonal antibodies and other recombinant proteins that address critical chronic diseases such as diabetes, cancer and autoimmune disorders.

Ranked among the Top 3 biosimilar players globally for rh-insulin and insulin glargine in volume terms, we are the first Indian company to launch a biosimilar in Japan with Insulin Glargine, which also has been approved for sale in EU and Australia. Our insulin products have made a difference to the lives of millions of people with diabetes across the globe. We now aim to provide our insulin products to ‘one in five’ people with diabetes in need of insulin-based therapy anywhere in the world within the next 10 years.

We are also making a huge impact in the area of cancer care. Our biosimilar Trastuzumab, which was the first to be approved anywhere in the world and launched in India in 2014, has helped treat several thousand HER2-positive metastatic breast cancer patients. We are also the first company from India to get its biosimilar approved by the USFDA; Ogivri™, co-developed by Biocon and Mylan, is the first biosimilar Trastuzumab to be approved in the US. In addition to Trastuzumab, several of our biosimilar assets are on track for anticipated regulatory approvals in developed markets.

We are also developing a pipeline of patented biologics to address global unmet medical needs. We have successfully launched a couple of novel biologics in India: Nimotuzumab for the treatment of head and neck cancer and Itolizumab to tackle psoriasis. Besides these, we have a basket of novel assets are under various stages of clinical development, including a high potential oral insulin.

Through our subsidiary, Syngene, we offer a suite of integrated, end-to-end discovery and development services for novel molecular entities (NMEs) to the global life sciences sector.

Ranked by the prestigious Science magazine among the Top 10 Best employers in the biotech industry, Biocon is passionately pursuing a mission to rationalize healthcare spends, enhance access to life-saving therapies and make a significant impact to global healthcare through ‘blockbuster’ drugs with the potential to benefit a billion patients.

Section iconCompany Overview

Headquarters
Hosur Road, Electronics City Bangalore, Karnataka 560100 IN
Phone number
+1-732-636-2950
Website
biocon.com
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
BICO1
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
1978
Employees
5001-10000

Section iconFunding & Financials

  • $129M

    Biocon has raised a total of $129M of funding over 1 rounds. Their latest funding round was raised on Feb 22, 2023.

  • $1B

    Biocon's revenue is in the range of $1B

Section iconFunding & Financials

  • $129M

    Biocon has raised a total of $129M of funding over 1 rounds. Their latest funding round was raised on Feb 22, 2023.

  • $1B

    Biocon's revenue is in the range of $1B

© LeadIQ, Inc. All rights reserved.